Clinical Trial

Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 30, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers. Furthermover, we conducted a comparative analysis of 68Ga-dPNE and 18F-FDG imaging to assess both the radiation dosimetry and diagnostic efficacy of 68Ga-dPNE.
Trial Details
NCT Number NCT06995976
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Conditions Malignant Tumour
Enrollment 30 participants
Start Date 2025-03-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-30